ClearPoint Neuro (CLPT) Aperçu de l'action
ClearPoint Neuro, Inc. est une société de dispositifs médicaux au stade commercial qui se concentre sur le développement et la commercialisation de plates-formes permettant d'effectuer des procédures chirurgicales mini-invasives dans le cerveau aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 1/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
CLPT Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ClearPoint Neuro, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$14.12 |
| Plus haut sur 52 semaines | US$30.10 |
| Plus bas sur 52 semaines | US$8.27 |
| Bêta | 1.24 |
| Variation sur 1 mois | -23.59% |
| Variation sur 3 mois | 25.96% |
| Variation sur 1 an | 25.73% |
| Variation sur 3 ans | 119.25% |
| Variation sur 5 ans | -36.48% |
| Évolution depuis l'introduction en bourse | -52.93% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jul 10
CLPT: Huntington’s Disease Partnership Will Drive Future Intracranial Procedure Upside
Analysts have lifted their price target on ClearPoint Neuro to $30 from $20, reflecting updated assumptions around a fair value of about $28.33 per share, a modestly lower discount rate, slightly higher modeled revenue growth, and a higher future P/E multiple tied to expectations for more visible revenue opportunities connected to uniQure's AMT-130 program. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed earnings guidance for 2026 and maintained its expected revenue range of $52 million to $56 million.
Mise à jour du récit • Jun 26
CLPT: Accelerated Huntington’s Approval Path Will Drive Future Revenue Opportunity
Analysts have lifted their price target on ClearPoint Neuro from $20 to $25, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E in light of ClearPoint's role as a direct beneficiary of the FDA-supported path to accelerated approval for uniQure's AMT-130 in Huntington's disease. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed its earnings guidance for 2026, maintaining expected revenue in the range of US$52 million to US$56 million.Seeking Alpha • Jun 18
ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case
Summary ClearPoint Neuro remains a speculative Buy, offering leveraged exposure to gene therapy commercialization and neurosurgery navigation growth. Recent FDA feedback on uniQure’s AMT-130 renews optimism for near-term revenue, but regulatory and partner execution risks persist. CLPT’s Q1 organic growth slowed, cash burn accelerated, and full-year 2026 revenue guidance ($52–$56M) disappointed versus expectations. Valuation is premium (8.06x EV/sales), justified by 26.8% projected revenue growth, but profitability hinges on partner drug launches and cash management. Read the full article on Seeking AlphaRecent updates
Mise à jour du récit • Jul 10
CLPT: Huntington’s Disease Partnership Will Drive Future Intracranial Procedure Upside
Analysts have lifted their price target on ClearPoint Neuro to $30 from $20, reflecting updated assumptions around a fair value of about $28.33 per share, a modestly lower discount rate, slightly higher modeled revenue growth, and a higher future P/E multiple tied to expectations for more visible revenue opportunities connected to uniQure's AMT-130 program. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed earnings guidance for 2026 and maintained its expected revenue range of $52 million to $56 million.Mise à jour du récit • Jun 26
CLPT: Accelerated Huntington’s Approval Path Will Drive Future Revenue Opportunity
Analysts have lifted their price target on ClearPoint Neuro from $20 to $25, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E in light of ClearPoint's role as a direct beneficiary of the FDA-supported path to accelerated approval for uniQure's AMT-130 in Huntington's disease. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed its earnings guidance for 2026, maintaining expected revenue in the range of US$52 million to US$56 million.Seeking Alpha • Jun 18
ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case
Summary ClearPoint Neuro remains a speculative Buy, offering leveraged exposure to gene therapy commercialization and neurosurgery navigation growth. Recent FDA feedback on uniQure’s AMT-130 renews optimism for near-term revenue, but regulatory and partner execution risks persist. CLPT’s Q1 organic growth slowed, cash burn accelerated, and full-year 2026 revenue guidance ($52–$56M) disappointed versus expectations. Valuation is premium (8.06x EV/sales), justified by 26.8% projected revenue growth, but profitability hinges on partner drug launches and cash management. Read the full article on Seeking AlphaMise à jour du récit • Jun 09
CLPT: Biopharma Partnerships And Intracranial Programs Will Drive Future Upside Potential
Analysts have lifted their price target on ClearPoint Neuro by $2, reflecting updated assumptions around discount rates, profit margins, and long term price-to-earnings (P/E) expectations. What's in the News ClearPoint Neuro reaffirmed revenue guidance for 2026, maintaining an expected range of US$52 million to US$56 million.Mise à jour du récit • May 26
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Upside Potential
Narrative Update: ClearPoint Neuro Analyst Price Target Revision Analysts now set a $22 price target for ClearPoint Neuro, down from $25. This reflects slightly lower modeled revenue growth and profit margins, along with a modestly reduced future P/E assumption, even as recent research highlights the company’s broad base of more than 60 biopharma partners and multiple clinical-stage programs with expedited review designations.Mise à jour du récit • Apr 20
CLPT: Biopharma Partnerships Will Drive Future Intracranial Program Adoption
ClearPoint Neuro's analyst price target has shifted by $2 as analysts weigh the recent FDA feedback on a partner's program in relation to the company's more than 60 active biopharma relationships and multiple expedited intracranial programs. Analyst Commentary Bullish Takeaways Bullish analysts see the reset price target of $18 per share as supported by what they view as a base business valuation of $12 per share, with additional value tied to pipeline and execution on intracranial programs.Mise à jour du récit • Apr 06
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Platform Adoption
Analysts have adjusted their price target on ClearPoint Neuro to $25.00, reflecting updated assumptions around the discount rate, margin expectations, and long term P/E benchmarks following recent research commentary. Analyst Commentary Recent research commentary on ClearPoint Neuro highlights a mix of optimism around the core business and caution linked to regulatory outcomes in partner programs, which feeds directly into updated valuation work and risk assumptions.Mise à jour du récit • Mar 22
CLPT: Broad Biopharma Partnerships And Intracranial Programs Will Drive Future Upside
Analysts have raised their price target on ClearPoint Neuro to $25 from $24, citing the company’s broad base of more than 60 biopharma partners and multiple clinical-stage intracranial programs as key supports for the updated valuation framework. Analyst Commentary Recent research on ClearPoint Neuro reflects a mix of renewed optimism and lingering caution, with analysts updating their valuation work after regulatory feedback on a key partner trial and reassessing the base business.Nouveau récit • Mar 21
Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders
Catalysts About ClearPoint Neuro ClearPoint Neuro provides minimally invasive neurosurgery systems and tools that support drug, cell and gene therapy delivery to the brain. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Mar 06
CLPT: Broad Biopharma Partnerships Will Support Future Neurology Platform Upside
Analysts have reduced their fair value estimate for ClearPoint Neuro from $29 to $24 and highlighted a lower $18 Street price target, citing higher perceived risk after the FDA feedback on a partner program, while still pointing to a broad biopharma customer base and multiple clinical-stage collaborations as key supports for the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts still see support for the updated valuation from more than 60 active biopharma partners, which suggests a diversified customer base rather than reliance on a single program.
Nouveau récit • Mar 06
IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential
Catalysts About ClearPoint Neuro ClearPoint Neuro develops and sells neurosurgical navigation, drug delivery and cranial access technologies used across preclinical research, clinical trials and hospital procedures. What are the underlying business or industry changes driving this perspective?Article d’analyse • Nov 10
ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues
The ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price has softened a substantial 39% over the previous 30 days...Article d’analyse • Nov 03
Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Sep 25
Why Investors Shouldn't Be Surprised By ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 84% Share Price Surge
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 84% after a shaky period...Article d’analyse • May 04
After Leaping 31% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Those holding ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares would be relieved that the share price has rebounded 31% in...Seeking Alpha • Apr 29
ClearPoint Neuro: Fundamentals Continue To Strengthen
Summary ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance. I continue to believe ClearPoint is an attractive investment opportunity, but its high revenue multiple, current lack of profitability and market volatility mean risk is elevated. Read the full article on Seeking Alpha
Nouveau récit • Mar 29
Cell And Gene Therapy Delivery Will Expand Global Partnerships
Strategic partnerships and global expansion aim to boost revenue and earnings through enhanced technology access and new pharma agreements.Article d’analyse • Feb 14
After Leaping 25% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have continued their recent momentum with a 25% gain in the last month...Article d’analyse • Dec 10
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shareholders have had their patience rewarded with a 26% share price jump in the...Article d’analyse • Sep 14
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Despite an already strong run, ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have been powering on, with a gain of 28...Article d’analyse • Aug 16
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Jul 11
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 26% after a shaky period...Article d’analyse • May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) just released its latest first-quarter results and things are looking bullish...Seeking Alpha • Apr 25
ClearPoint Neuro: Macro-Induced Multiple Compression
Summary ClearPoint Neuro's stock is down due to a recent equity raise and concerns about rising interest rates. The company is expanding its product portfolio and driving adoption of existing products with new software releases and FDA clearances. The recent capital raise should be sufficient to see the ClearPoint through to profitability. ClearPoint's valuation is modest given the company's rapid growth and expanding product portfolio. Read the full article on Seeking AlphaArticle d’analyse • Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for ClearPoint Neuro is US$4.02 based on 2 Stage Free Cash Flow to Equity Current...Article d’analyse • Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Shareholders of ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) will be pleased this week, given that the stock price is up 19...Rendement pour les actionnaires
| CLPT | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -6.8% | -0.7% | -1.0% |
| 1Y | 25.7% | -20.7% | 14.7% |
Rendement vs Industrie: CLPT a dépassé le secteur US Medical Equipment qui a rapporté -20.7 % au cours de l'année écoulée.
Rendement vs marché: CLPT a dépassé le marché US qui a rapporté 14.7 % au cours de l'année écoulée.
Volatilité des prix
| CLPT volatility | |
|---|---|
| CLPT Average Weekly Movement | 12.2% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: Le cours de l'action de CLPT a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CLPT ( 12% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1998 | 172 | Joe Burnett | www.clearpointneuro.com |
ClearPoint Neuro, Inc. est une société de dispositifs médicaux en phase de commercialisation qui se concentre sur le développement et la commercialisation de plates-formes permettant d'effectuer des procédures chirurgicales mini-invasives dans le cerveau aux États-Unis. La société propose des systèmes ClearPoint, tels que le matériel ClearPoint, qui comprend un cadre de fixation de la tête, un poste de travail informatique et un moniteur en chambre, et les produits jetables ClearPoint, qui comprennent le dispositif de trajectoire SmartFrame, un contrôleur manuel et des accessoires connexes, ainsi que la canule SmartFlow Neuro. Elle propose également le logiciel ClearPoint, qui guide le médecin dans la planification chirurgicale, l'alignement du dispositif, la navigation vers la cible et le suivi de la procédure ; le système de thérapie laser ClearPoint Prism Neuro pour nécroser ou coaguler les tissus mous ; et le système IRRAflow, une plateforme active d'échange de fluides.
ClearPoint Neuro, Inc. Résumé des fondamentaux
| CLPT statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$423.45m |
| Bénéfices(TTM) | -US$29.07m |
| Recettes(TTM) | US$40.61m |
10.4x
Ratio P/S-14.6x
Ratio P/ELe site CLPT est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CLPT compte de résultat (TTM) | |
|---|---|
| Recettes | US$40.61m |
| Coût des recettes | US$15.30m |
| Marge brute | US$25.32m |
| Autres dépenses | US$54.38m |
| Les revenus | -US$29.07m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Aug 03, 2026
| Résultat par action (EPS) | -0.97 |
| Marge brute | 62.33% |
| Marge bénéficiaire nette | -71.57% |
| Ratio dettes/capitaux propres | 263.5% |
Quelles ont été les performances à long terme de CLPT?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/26 22:23 |
| Cours de l'action en fin de journée | 2026/07/24 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
ClearPoint Neuro, Inc. est couverte par 7 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |